Answer
Based on in vitro data, Tepmetko’s tepotinib or its metabolite may alter metformin exposure in humans by inhibiting its renal excretion or hepatic uptake via OCT1 and 2 and MATE1 and 2; monitoring metformin’s clinical effects is recommended during co-administration.
Sources for this answer
- TEPMETKO 225 mg film-coated tabletsMerck · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated
Sources checked